The Supreme Court declined to hear an appeal in the case of former InterMune CEO W. Scott Harkonen, who claimed that information he disseminated about a clinical trial was protected speech under the First Amendment. The FDA said the press release in question contained false and misleading statements.

Full Story:

Related Summaries